Researchers have identified a natural defense mechanism within the human body that may explain why some people remain asymptomatic even after being infected with the influenza virus. A study led by the Fisabio Foundation found that dermcidin, an antimicrobial peptide produced constitutively by the body, can block influenza infections by preventing the virus from entering human cells.
While influenza infections are common, approximately one-fifth of infected individuals do not develop symptoms. The mechanisms behind this resilience have long been unclear, but the discovery of dermcidin’s antiviral activity provides a potential biological explanation. Data indicates that individuals who remain asymptomatic tend to have higher levels of dermcidin than those who become susceptible to the disease.
Blocking the virus at the door
The effectiveness of dermcidin lies in its ability to target hemagglutinin, a critical protein that the influenza virus uses to gain entry into a host cell. Specifically, the peptide attaches to a highly conserved region of the protein involved in membrane fusion. [internal link: antiviral mechanisms] By binding to this area, dermcidin alters the protein’s structure, which prevents the virus from fusing with the cell membrane and initiating an infection.
This protective action is not limited to the flu. The researchers found that dermcidin’s antiviral effects extend to taxonomically unrelated respiratory viruses, including the measles virus and human coronavirus OC43.
Research Context: Hemagglutinin
Hemagglutinin is a protein found on the surface of influenza viruses. It acts as a key that allows the virus to “unlock” and enter a cell. By blocking this protein, dermcidin essentially jams the lock, leaving the virus unable to infect the cell.
Biological presence and clinical potential
Dermcidin is present in all anatomical regions associated with the entry routes of respiratory viruses, including respiratory tissues and sweat. The study observed that levels of this peptide increase during viral respiratory infections, suggesting the body naturally ramps up production to fight the virus. [internal link: respiratory health defenses] Tests conducted in vitro and in vivo, including studies on mice, confirmed that dermcidin protects against influenza disease.

Because dermcidin is a human-derived molecule, researchers suggest it has potential as a basis for new products designed to prevent and treat respiratory viral infections. However, these findings currently represent a research milestone rather than an available medical treatment.
Common Questions
Is there a dermcidin supplement or medication I can take?
No. The research identifies dermcidin as a naturally occurring peptide in the body and suggests its potential for future human-derived products, but it is not currently a commercial treatment or supplement.
Does this mean sweat can cure the flu?
While dermcidin is found in sweat, the research focuses on the peptide’s biological mechanism in blocking viral entry into cells. It is a component of the body’s innate immune response, not a topical cure.
Could these findings lead to a new generation of broad-spectrum antivirals that target multiple types of respiratory viruses?





